Teitur reports positive early data for Parkinson’s peptide TT‑P34
Phase 1 trial shows strong safety and CNS exposure

Read the full article on the original site.
Read Full ArticlePhase 1 trial shows strong safety and CNS exposure

Read the full article on the original site.
Read Full Article